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1. Introduction
Severe cutaneous adverse reactions (SCARs) are generally induced by drugs and encompass
the conditions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN),
drug induced eosinophilia and systemic syndrome (DRESS) also known as drug induced
hypersensitivity syndrome (DIHS), and acute generalized exanthematous pustulosis
(AGEP). These conditions, although rare, cause significant morbidity and are potentially fa‐
tal. It is therefore important for the treating physician to promptly recognize SCARs through
the identification of their characteristic clinical features so that the offending drug is
promptly withdrawn and supportive and adjunctive therapies are administered. SCARs are
accompanied by particular abnormalities on routine laboratory investigations and skin biop‐
sy that enables confirmation of the diagnosis and provision of useful prognostic informa‐
tion. Data bases have been established, predominantly in Europe, since the 1980s to
characterize the epidemiology of SCARs including the identification of drugs with the high‐
est relative risk and the latency between the commencement of drug intake and the onset of
clinical manifestations. The pathogenesis of the various SCARs involves delayed T cell-
mediated inflammation in a genetically predisposed individual and in the case of DIHS,
may involve viral factors. The emerging field of the genetic susceptibility to SCARs has
raised the important issue of pharmacogenetic screening as a method of predicting an indi‐
vidual’s risk of developing SCAR to a certain drug. The treatment of SJS/TEN is dependent
on supportive care in a suitable settling such as a Burns Unit and the role of immunomodu‐
latory agents is not well defined and is not robustly supported in the literature by prospec‐
tive studies. The evidence for the use of immunomodulatory agents and ganciclovir is
emerging in the treatment of DIHS/DRESS. AGEP usually has favourable prognosis if the
offending drug is withdrawn but a course of corticosteroids may hasten recovery.
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1.1. SJS/TEN
Stevens-Johnson Syndrome (SJS), first described in 1922 as an acute mucocutaneous syndrome
in two boys, and Toxic Epidermal Necrolysis (TEN), first described as a scalding eruption of
the skin in 1956 in four patients, are now considered to lie along the spectrum of epidermal
necrolysis. The terminology is based on the extent of epidermal detachment; SJS indicates that
there is less than 10% detachment of the body surface area, TEN greater than 30%, and
SJS/TEN overlap between 10 and 30%.
The clinical presentation is characterized by a rash featuring target-like lesions, and mucositis
involving the ocular, oropharyngeal and genital surfaces. The patient is also systemically
unwell with fever and malaise. The EuroSCAR case control study collected 379 cases of
SJS/TEN between 1997 and 2001 from 6 countries encompassing over 100 million inhabitants.
The estimated incidence is 1-2 per million per year. The drugs associated with the highest
relative risk include allopurinol, antibacterial sulphonamides, oxicam non-steroidal anti-
inflammatory drugs (NSAIDs), aromatic anticonvulsants (phenytoin, carbamazepine, pheno‐
barbital), lamotrigine, and nevirapine. The latency between the intake of these high-risk drugs
and the onset of clinical manifestations is 1 to 8 weeks. Other factors influencing risk include
the presence of other diseases (HIV, malignancy, autoimmune disease, recent radiotherapy,
acute infection within the last four weeks) and pharmacokinetic factors (dose of allopurinol
commenced at 200-300 mg daily). Recently, genes conferring strong susceptibility to SJS/TEN
have been identified, the most prominent of which are HLA-B*1502 and carbamazepine in
individuals of Asian ancestry, HLA-A*3101 and carbamazepine in individuals from Northern
European ancestry, and HLA-B*5801 and allopurinol in various racial groups. A black box
warning has been placed by the Food and Drugs Administration and Health Canada alerting
physicians to not only to be aware of the risk of carbamazepine and SJS/TEN in Asians but to
also screen at risk individuals for the susceptibility allele. Currently, this strategy has been
limited by the lack of availability of cost-effective pharmacogenetic testing methods to the
general physician.
The immunopathogenesis of SJS/TEN involves the release of granulysin by CD8 cytotoxic T
cells and natural killer cells within the epidermis resulting in apoptosis of keratinocytes.
Apoptosis may also result from the degranulation of perforin and granzyme by CD8 cytotoxic
T cells and the ligation of Fas on keratinocytes by Fas-ligand (Fas-L). The source of Fas-L is
still unclear with CD8 cells and keratinocytes proposed as candidates. Histologically, the
resultant widespread apoptosis of keratinocytes results in necrosis of the epidermis and
dermoepidermal separation at the level of the stratum spinosum. Direct immunofluorescence
of skin biopsies in SJS/TEN is negative differentiating it from autoimmune vesiculobullous
diseases.
The diagnosis is made clinically and confirmed histologically. Skin testing is contraindicated
given the risk of precipitating a generalized reaction. In vitro tests are currently not widely
available and relatively poor sensitivity. Lymphocyte transformation tests that assess the
proliferative response of T cells to the drug have a sensitivity of 60-70% and are more likely to
be positive if performed within 6 weeks of the onset of the disease. Cytotoxicity assays that
Skin Biopsy - Diagnosis and Treatment46
determine the extent of degranulation of cytotoxic T cells by flow cytometry or ELISA may
prove useful in the future.
The treatment of SJS involves the removal of the offending drug and supportive treatment
depending on severity and availability in a burns unit to address the manifestations and
complications of acute skin failure including monitoring of fluid-electrolyte balance, provision
of enteral or parenteral nutrition, wound care and treatment of sepsis. In addition, supportive
care of affected mucosal surfaces is required. This includes aggressive ocular lubrication,
topical corticosteroids and topical antibiotics, hygienic mouthwashes and topical oral anaes‐
thetics, and monitoring for urinary retention. Large randomized trials on the benefits of
immunomodulatory therapy is lacking but there is sufficient evidence to recommend the
administration of intravenous immunoglobulin (IVIg) as it contains anti-FasL antibodies and
as a result may halt further epidermal necrosis and hasten re-epithelialization. Cyclosporin
due to its effects on cytotoxic T cell depletion has reported to be of benefit in a number of small
studies. A number of early studies revealed that systemic corticosteroids may be not be
beneficial in the treatment of SJS/TEN and in fact may be harmful by promoting sepsis but
these conclusions may have been partly explained by the inadequate doses administered and
the delay in initiating treatment. Recent studies have demonstrated benefit in the immediate
use of high dose pulse methylprednisolone, especially in reducing the rate of ocular compli‐
cations. The application of amniotic membranes to the conjunctival surface may also prove
beneficial in minimising ocular sequelae such as dry eye, cicatrization and in rare cases, corneal
perforation.
The mortality rate of SJS/TEN is high; approximately 10% for SJS and 50% for TEN. A score
for the evaluation of TEN (SCORTEN) has proven remarkably accurate in predicting mortality
through identification of 6 risk factors; age > 40 years, presence of malignancy, heart rate > 120/
min, epidermal detachment > 10%, serum urea > 10 mmol/L (28 mg/dL), serum glucose > 14
mmol/L (252 mg/dL) and serum bicarbonate < 20 mmol/L (20 mEq/L).
2. DIHS/DRESS
DIHS/DRESS is also referred to as hypersensitivity syndrome and when caused by antiepi‐
leptic drugs it has been often referred to as anticonvulsant hypersensitivity. The condition is
characterised by fever, rash, lymphadenopathy, eosinophilia and/or other leukocyte abnor‐
malities, and internal organ involvement such as hepatitis. Reactivation of human herpes virus
(HHV)-6 is also considered by some groups to be an instrumental component of the condition.
The rash typically begins as patchy erythematous macules that become confluent and pro‐
gresses especially if the causative drug is not withdrawn to an erythroderma or exfoliative
dermatitis. The syndrome typically develops between 3 weeks and 3 months after the starting
therapy and a limited number of drugs appear involved in its causation. They include
anticonvulsants (phenytoin, carbamazepine, phenobarbital, lamotrigine, zonisaminde),
allopurinol, sulphonamides (dapsone, sulphasalazine), antiretrovirals (abacavir, nevirapine),
minocycline, strontium ranelate, and mexilitene. The precise incidence according to the latest
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case definition will be determined by RegiSCAR study, which comprises data collected from
6 European countries and the JSCAR Japanese registry. The incidence following phenytoin
therapy is estimated to be 1 in 1000 to 10000 exposures.
DIHS has a relapsing remitting course lasting several weeks to months despite the withdrawal
of the offending drug and this has been postulated to result from the sequential reactivation
of herpes viruses analogous to that observed in graft versus host disease. The precise role of
HHV-6 in DIHS is unclear. One theory is that HHV-6 triggers DIHS through its reactivation
within T cells resulting in HHV-6 stimulated T cells cross-reacting with the culprit drug,
following which there is sequential activation of heterologous herpes viruses. The alternative
explanation is that drug specific T cells are activated resulting in reactivation of the viral
genome and sequential reactivation of herpes viruses.
The histological features of DIHS are relatively non-specific and typically comprise a superfi‐
cial perivascular lymphocytic infiltrate. As the understanding of the disease mechanisms
emerge, novel findings such as granulomatous inflammation have also been identified.
The diagnostic criteria consist of the typical clinical features and laboratory abnormalities.
Confirmation of the role of the causative agent by skin testing is contraindicated because of
the risk of a generalized reaction. The utility of LTTs is unclear as they are often negative early
in the course of disease possibly as a result of regulatory T cell activation. LTTs may become
positive after 5-7 weeks as the expanded regulatory T cell population are removed by apoptosis
at the end of the immune response.
A prolonged course of oral corticosteroids is required to treat DIHS given the relapsing
remitting nature of the condition. The mortality rate is estimated to be 10-20%.
3. AGEP
AGEP is rare with an incidence of 1-5 cases per million per year. The clinical manifestations
are characterised by fever and the rapid appearance of disseminated sterile pustules 3-5 days
after the commencement of treatment. It is accompanied by a marked neutrophilia. Mucous
membranes are not typically involved. The drugs conferring the highest risk of AGEP
according to the EuroSCAR study are aminopenicillins, pristinamycin, hydroxychloroquine,
antibacterial sulphonamides, terbinafine and diltiazem. The pathogenesis of AGEP involves
the initial influx of CD8 cytotoxic T cells resulting in apoptosis of keratinocytes and formation
of vesicles. Then CXCL-8 producing CD4 cells enter the epidermis resulting in neutrophil
mediated inflammation and formation of pustules. As a result the histology reveals intraepi‐
dermal usually subcorneal pustules and an accompanying neutrophilic and lymphocytic
infiltrate. Epicutaneous patch testing may also support the diagnosis by causing a localized
pustular reaction 48-96 hours after the offending drug is applied. The condition usually
resolves by 15 days after the causative drug is withdrawn but oral corticosteroid therapy may
be necessary in some individuals. The mortality rate is up to 5% and mostly occurs in the
elderly who have significant comorbidities.
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4. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
4.1. History and nosology
SJS and TEN were once considered as variants of erythema multiforme (EM), a condition first
described by Ferdinand von Hebra in 1860 [1] as a mild and relapsing eruption of target lesions
affecting the acral regions. Mucosal involvement occurs in up to 70% of cases of EM. In 1922,
two American paediatricians, Albert Stevens and Frank Johnson, described two cases of fever,
stomatitis, purulent conjunctivitis, and a generalized eruption of purple papules in boys aged
7 and 8 years, respectively [2]. Both cases were distinguished from EM by the prolonged high
fever, and the generalized distribution and heavy terminal crusting of the skin lesions. Bernard
Thomas proposed two categories of EM in 1950: erythema multiforme minor, as described by
von Hebra, and erythema multiforme major, a severe form that encompassed SJS [3]. Alan
Lyell, a Scottish dermatologist, termed the condition toxic epidermal necrolysis (TEN) after
reporting four cases of an acute life threatening mucocutaneous disorder characterized by
diffuse erythema followed by extensive epidermal detachment manifesting as blistering and
sloughing of the skin [4]. Although SJS and TEN were initially considered distinct entities, it
was later proposed that they form a continuum along the same disease process and differ
mainly in the extent of involvement [5],[6]. It was also proposed that EM major and SJS are
distinct conditions, with EM major characterised by acral target-like lesion typical of EM minor
but with mucosal involvement. SJS was applied to cases of mucous membrane involvement
and a more extensive eruption of atypical targetoid lesions, blisters or sloughing of the skin [7].
The distinction between EM and SJS are consistent with observations regarding differences in
etiology, demography and histopathology and not just confined to variations in the severity
of disease. Most cases of EM are related to infection especially those with recurrent disease,
which is related to herpes simplex virus (HSV) infection [8]-[10] in contrast to SJS which usually
is an idiosyncratic reaction to drugs [11]. EM typically affects young adults in their 20s and 30s
although approximately 20% of cases involve children [12],[13] whereas SJS/TEN occurs at any
age [11]. Histopathology in EM in contrast to SJS/TEN consists of a denser infiltrate of
lymphocytes and less apoptosis of keratinocytes [14].
In 1993, a classification scheme was proposed that is widely but not universally adopted that
arbitrarily defines SJS and TEN according to the extent of epidermal detachment [7]. In SJS,
epidermal loss affects less than 10% of the total body surface area (TBSA) whereas TEN
involves greater than 30% of the TBSA. Epidermal detachment between 10 and 30% of the
TBSA is classified as SJS/TEN overlap.
4.2. Epidemiology
The epidemiology of SJS/TEN and other severe cutaneous adverse reactions (SCARs) has been
more accurately determined in recent years due to registries that have been established mainly
across Europe comprising cases that are reviewed by expert committees and based on
predefined and validated criteria. A population-based registry was commenced in Germany
in 1990 to collect all hospitalised cases of SJS, TEN and EM major [15]. An international case-
control study was conducted between 1989 and 1995 in France, Germany, Italy and Portugal
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(SCAR study) focusing on cases of SJS/TEN requiring hospitalisation [16],[17]. A European
case-control surveillance study of SCARs (EuroSCAR study) was conducted between 1997 and
2001 in Austria, France, Germany, Israel, Italy, and the Netherlands investigating both
SJS/TEN [11] and AGEP [18] that resulted in admission to hospital. In 2003, the European
registry on SCARs (RegiSCAR) was commenced collecting biological samples across the same
countries that participated in the EuroSCAR study. This network, which is focused on SJS/TEN
and AGEP, has spawned numerous studies on epidemiology, pharmacogenetics and histopa‐
thology and includes community cases that requiring hospitalisation as well as cases that
developed during hospital admissions. These registries not only provide valuable information
on the epidemiology of SCAR but they have enabled close scrutiny of the availability and
prescription of high-risk drugs. For example, the SCAR study resulted in the withdrawal of
chlormezanone from the market and restricted indications for cotrimoxazole and phenobar‐
bitol [17].
The incidence of SJS/TEN is 1-2 cases/million inhabitants/year [15]. The EuroSCAR study
published in 2008 comprised 379 cases that included 134 cases of SJS, 136 cases of SJS/TEN
overlap, and 109 cases TEN spanning a geographical area encompassing over a 100 million
inhabitants. The median age of cases was found to be 50 years (range 1-95 years), and a female
preponderance (62% of cases) was noted [11].
4.3. Etiology
4.3.1. Drugs
Drugs are nearly always the cause of SJS/TEN. Over 220 medications have been implicated but
only relatively a few are responsible for the majority of cases. The EuroSCAR study comprised
379 cases of SJS/TEN and 1505 age-matched controls, who were patients admitted to hospital
for other acute illnesses [11]. Univariate relative risk (uRR) and multivariate relative risk (mRR)
were calculated for each drug suspected of causing SJS/TEN. The drugs found to confer the
highest risk were cotrimoxazole (uRR 102), other anti-bacterial sulphonamides (uRR 53),
carbamazepine (mRR 72), nevirapine (uRR >22), allopurinol (mRR 18), phenytoin (mRR 17),
oxicam-NSAIDs (mRR 16), lamotrigine (uRR >14), and sertraline (mRR 11). Drugs that were
found to have a significant but lower risk included acetic acid-NSAIDs, macrolides, quino‐
lones, cephalosporins, tetracyclines and aminopenicillins. SJS/TEN typically occurs with drugs
that are taken on a long-term basis. The median latency between the onset of medication use
and the occurrence of SJS/TEN in the EuroSCAR study was found to be less than 4 weeks (range
1-8 weeks): carbamazepine 15 days, phenobarbitol 17 days, allopurinol 20 days, phenytoin 24
days. Pantoprazole and tramadol were associated with high uRRs, 18 and 20, respectively, but
the frequent co-medication with highly suspected drugs and the timing of the onset of
SJS/TEN were not suggestive of a true risk. Commonly used medications not associated with
a risk of SJS/TEN included beta-blockers, ACE-inhibitors, calcium channel blockers, thiazide
diuretics, furosemide, propionic acid-NSAIDs, sulphonylureas, and insulin. Interestingly,
valproic acid was not shown to have a significant risk, which is in contrast to previous
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observations [17],[19]. The most likely explanation is that valproic acid was frequently
coadministered with high-risk drugs.
A pooled analysis of the SCAR and EuroSCAR data was performed for children under 15 years
of age and showed that anti-bacterial sulphonamides, phenobarbitol, lamotrigine and carba‐
mazepine were strongly associated with SJS/TEN in this paediatric population [20].
4.3.2. Other causes
Infection with Mycoplasma pneumoniae is a known cause of SJS especially in the paediatric
population and a few cases of TEN have been reported to complicate infection with this agent
[13],[21]. However, the EuroSCAR study, failed to show that infection is a risk factor on its
own although there is a suggestion that it may modestly increase the risk of SJS/TEN from
medication. SJS/TEN has been reported in association with vaccinations [22] and exposure to
industrial chemicals and fumigants [23].
4.4. Clinical presentation
SJS/TEN is characterized, as per the original descriptions, by fever, blistering skin eruption
and severe mucositis [2],[4]. The skin lesions initially appear as atypical target –like or targetoid
lesions, which are erythematous macules that contain a central purpuric blister (Fig. 1). Lesions
Figure 1. Atypical target-like or targetoid lesions in a patient with SJS characterized by an erythematous macule with
a central blister.
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are symmetrically distributed often starting on the face and thorax before spreading to other
areas (Fig. 2). The scalp is typically spared. Blisters result from epidermal detachment and they
are easily breached resulting in dark red oozing erosions. Lesions exhibit Nikolsky’s sign,
which is epidermal separation induced by gentle lateral pressure applied to the skin surface.
The skin then sloughs rapidly over several days as a result of separation of large sheets of the
epidermis from the dermis. Fulminant cases of TEN have been reported were total loss of the
epidermis occurs within 24 hours [24]. New lesions may continue to erupt for up to 4 weeks.
However, the growth of a new epithelium occurs after several days and individual lesions are
completely re-epithelialized after a mean of 3 weeks. Cicatrization of the mucous membranes
may take longer to complete.
At least two mucosal surfaces are involved in 90% of cases of SJS/TEN [25]. Oropharyngeal
involvement causes severe pain and odynophagia as a result of erosion and crusting (Fig. 3).
Ocular regions may show a purulent conjunctivitis, pseudomembrane formation and corneal
ulceration as a result of sloughing of conjunctival and corneal epithelia (Fig. 4). Urethritis may
result in dysuria and even urinary retention. Sloughing of the tracheal and bronchial epithe‐
lium occurs in up to 30% of cases and may result in hypoxia, bronchial hypersecretion,
pulmonary edema and bronchiolitis obliterans and the need for mechanical ventilation [26],
[27]. The gastrointestinal tract can also be involved resulting in per rectal bleeding [28].
The mortality of SJS is generally below 10% whereas 30-50% of TEN patients die in the acute
phase of the illness mostly as a result of skin failure. Infection and sepsis with multiorgan
failure is the most common of death. The causative organisms are usually Staphylococcus
aureus and Pseudomonas aeruginosa [29]. Fluid and electrolyte imbalances occur as a result of
increased transepidermal water loss and impaired intake of nutrition due to odynophagia from
stomatitis. Less common fatal complications include adult respiratory distress syndrome,
pulmonary embolism and gastrointestinal haemorrhage [30],[31]. Mortality is accurately
predicted by the SCORTEN scale (Table 1) and should be computed within 24 hours and 3
days following admission [32]-[34].
Chronic complications occur frequently following the acute phase of SJS/TEN. The most
serious sequelae relate to the eye. The chronic ocular consequences are that of a cicatrization
of the conjunctiva and symblepharon formation, severe dry eye, trichiasis, eyelid margin
keratinization, and limbal stem cell deficiency, all of which combine to cause corneal ulceration
and scarring and loss of vision (Fig. 5) [35],[36]. Patients may also experience chronic photo‐
phobia and eye pain [37]. Skin sequelae include scarring, pigmentation abnormalities, and
shedding of hair and nails [38]. Vulvovaginal involvement can result in stenosis [39]. Vulvar
adenosis can occur in young women several years after resolution of the acute episode and
can present with tender, erosive, haemorrhagic lesions [40]. Phimosis can occur in men [41].
Bronchopulmonary complications confer a poor prognosis and include chronic bronchitis,
bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia, bronchiectasis
[42],[43] Oesophageal stricture and webbing has also been described and can result in
dysphagia [44].
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Figure 2. Symmetrical distribution of targetoid lesions in a patient with SJS, which typically first appear on the face
and thorax before spreading to other areas.
Severe Cutaneous Adverse Reactions
http://dx.doi.org/10.5772/54820
53
Figure 3. Oral mucositis in a patient with SJS depicted as sloughing, necrosis and crusting of the inner labial surfaces.
Figure 4. Purulent conjunctivitis in a patient with SJS accompanied by pseudomembrane formation, which results
from sloughing of conjunctival and corneal surfaces.
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Severe Cutaneous Adverse Reactions Severe Cutaneous
Adverse Reactions
Age >40 years 1
Presence of malignancy 1
Heart rate >120/min 1
TBSA involved >10% 1
Serum urea > 10 mmol/L (28 mg/dL) 1
Serum glucose >14 mmol/L (252 mg/dL) 1
Serum bicarbonate <20 mmol/L (20 mEq/L) 1
SCORTEN Mortality (%)
0-1 3.2
2 12.1
3 35.3
4 58.3
≥5 90
Table 1. SCORTEN
4.5. Pathogenesis
SJS/TEN results from the T- and NK-cell mediated extensive apoptosis of keratinocytes. The
pharmaco-immune (p-i) concept, the mechanism by which the drug binds directly with the T
cell receptor (TCR) causing activation of proapoptotic pathways. Granulysin is the major
mediator of apoptosis in SJS/TEN. Apoptosis is also mediated through involved Fas-FasL
interaction, and the release of granzyme and perforin.
4.5.1. The pharmaco-immune (p-i) concept
It is generally accepted that in SJS/TEN, the parent drug binds directly and non-covalently to
the MHC and the TCR of primed effector and memory T cells [45]. Naïve T cells are not
sufficiently stimulated by a p-i drug and additional signals are required [46]. T cells may be
primed by infection or autoimmune disease resulting in high cytokine levels such as IL-2 and
IFN-γ resulting in increased expression of MHC and costimulatory molecules. This may
provide an explanation for the increased incidence of drug hypersensitivity in inflammatory
and infectious diseases. The drug may also bind to toll-like receptors resulting in the expression
of costimulatory molecules by dendritic cells. For drugs such as cotrimoxazole, lamotrigine,
and carbamazepine, the p-i concept may not be the sole mechanism involved; metabolites may
also play a role through haptenization [47].
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4.5.2. Granulysin
A recent study by Chung et al using global gene expression profiling showed that granulysin
RNA was the most significant cytotoxic molecule expressed in blister cells from patients with
SJS/TEN. Granulysin protein concentrations were 2-4 times higher than perforin, granzyme B,
and FasL and depleting granulysin reduced cytotoxicity [48]. Granulysin is a cationic cytolytic
protein produced by CTL, NK and NKT cells [49]. The 15-kDa-precursor form, found in blister
fluid, induced skin necrosis when injected into mice and exhibited significant cytotoxicity in
vitro. This contrasted with the minimal cytotoxicity induced by perforin, granzyme B, and
FasL [48]. Granulysin is also a proinflammatory molecule that causes an increase in the
expression of chemokines (RANTES/CCL5, MCP-1, MCP-3, MIP-1α/CCL3) and cytokines
(IL-1, IL-6, IFN-α) resulting in the recruitment of T cells, monocytes and other inflammatory
cells [50].
4.5.3. Fas-FasL, perforin/ granzyme and TNF pathways
Viard et al, showed that the binding of FasL to Fas expressed on the surface of keratinocytes
resulted in their apoptosis [51]. The cytoplasmic death domain of Fas undergoes conforma‐
tional changes and trimerization upon recognition of FasL. This results in the recruitment of
the Fas-associated death domain (FADD), which binds to procaspase 8 resulting in triggering
Figure 5. Cicatrization of the bulbar and palpebral conjunctival surfaces with resultant symblepharon formation,
shortening of the fornix, and distichiasis.
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of the caspase cascade and apoptosis. The source of the FasL is unclear. Viard et al showed
that the FasL was is present on the surface of keratinocytes and in the serum of patients with
TEN but not on the surface of keratinocytes or in the serum of patients with maculopapular
exanthems and normal controls [51]. A further study demonstrated that FasL was not consti‐
tutively expressed on the surface of keratinocytes but are transported to the cell membrane
after damage to the keratinocyte [52]. Abe et al, however, found that the source of FasL was
PBMCs and not keratinocytes [53].
Nassif et al showed that mononuclear cells from blister fluid induce cytotoxicity via perforin
and granzyme B [54]. This cytotoxicity was blocked by inhibiting perforin/granzyme but not
by inhibiting Fas. Perforin and granzyme are proteins stored in the granules of CTLs. Upon
recognition of a target cell, the CTL releases perforin, which create 16-nm channels in the target
cell membrane. Granzyme B, a protease passes through these channels to activate the caspase
cascade. The loss of T regulatory cell function in the acute stage of SJS/TEN may further
contribute to the epidermal damage caused by effector T cells [55].
Posadas et al, showed that both Fas-FasL and perforin/granzyme pathways may be involved
in SJS/TEN. They found a direct correlation between disease severity and levels of perforin
and granzyme B in patients with maculopapular exanthems, SJS and TEN. FasL was detected
in the PBMCs and blister fluid of patients in SJS and TEN but not in those in maculopapular
exanthema, suggesting that Fas-FasL is involved in more severe reactions [56].
Nassif et al, also showed a potential role for cytokines in the pathogenesis of SJS/TEN. He
found elevated levels of IFN-γ, soluble TNF, IL-10, soluble FasL in the blister fluid of TEN
patients. Although they disputed the central role of FasL, they hypothesised that drug specific
CTLs secrete IFN-γ, which activates keratinocytes to produce TNF, a cytokine that upregulated
MHC class I molecules. This increases exposure of keratinocytes to CTL resulting in perforin/
granzyme-mediated apoptosis. IL-10 serves to downregulate the inflammatory reaction [57].
More recently, TRAIL (TNF related apoptosis inducing ligand) and TWEAK (TNF-like weak
inducer of apoptosis) were shown to be present in blister fluid from TEN patients [36]. They
are released by CD1a and CD14 cells and initiate apoptosis of keratinocytes in a MHC-class I-
independent manner.
4.6. Risk factors for SJS/TEN
4.6.1. Genetic susceptibility
It was observed in the 1990s that the most commonly offending drugs varied among different
ethnic populations. In Western countries, the most commonly implicated agents of SJS/TEN
were NSAIDs and sulphonamides [17]. In contrast, carbamazepine was found to be the leading
cause of SJS/TEN in Southeast Asian countries, including India, Malaysia, Singapore, Taiwan
and Hong Kong [58]. Interestingly, carbamazepine in Western countries causes more cases of
DIHS than SJS/TEN. Allopurinol is also a frequent case of SJS/TEN and DIHS but does not
appear to have a racial bias [59].
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The most striking genetic association was detected in a cohort of Han Chinese in Taiwan,
where the HLA-B*1502  allele was found in 100% of the 44 patients with carbamazepine-
induced SJS/TEN and only 3% of the carbamazepine-tolerant individuals;  OR 2504 [126–
49522] [60].  These findings were replicated in an extended cohort of subjects of Chinese
descent  originating  from separated  geographic  areas  of  China,  Taiwan,  and  the  United
States  [61].  This  association  with  carbamazepine-induced  SJS/TEN,  however,  was  not
found in  individuals  with  European [62]  and Japanese  ancestries  [63],  respectively,  and
therefore the allele appears relevant in the context of ethnicity. In a recent study compris‐
ing 12  patients  of  Northern European ancestry  with  carbamazepine-induced SJS/TEN,  5
(42%)  carried the  HLA-A*3101  allele,  as  compared with  10  (4%)  of  the  257  control  sub‐
jects; OR 25.93 [4.93-116.18] [64]. The results of this study are yet to be replicated in other
cohorts  of  subjects  with  Northern  European  ancestry.  In  a  Japanese  study,  The  HLA-
A*3101  allele  was  found  in  5/6  (83.3%)  carbamazepine-induced  SJS/TEN  compared  to
47/376 (12.5%) carbamazepine-tolerant patients; OR 33.9 [3.9-295.6]. Larger patient sample
sizes are required to confirm this association in the Japanese where the allele frequency is
9% [65]. Interestingly the HLA-A*3101 allele was shown to be associated with maculopap‐
ular exanthem (OR 17.5 [4.6-66.5]) but not SJS/TEN in a Han Chinese population [66].
A study comprising a Han Chinese cohort in Taiwan demonstrated the presence of the HLA-
B*5801 allele in all 51 patients with allopurinol-induced SCAR (21 with TEN, 30 with DIHS)
compared with only 15% (20/135) in allopurinol-tolerant subjects; OR 580.3 [34.4-9780.9] [67].
The role of these HLA alleles in the pathogenesis of SCAR is unclear. Certain HLA alleles may
bind to particular drugs more robustly than other alleles. Furthermore, the binding of the drug
in SJS/TEN is MHC class I restricted, which is consistent with the prominent role of CD8 cells
in the pathogenesis of the disease. If an allele has a functional effect that may play a role in the
pathogenesis of disease, this association will be consistently observed across different popu‐
lations. The differences observed between the Chinese and European studies may be partly
explained by the fact that pharmacogenetic studies are likely to yield positive results when
conducted in a population with a high frequency of such an allele [69]. The risk of disease from
a genetic polymorphism is influenced by its prevalence. The HLA-B*1502 allele frequency is
4.8 to 12.8% in Southeast Asians compared to 0-0.1% observed in Northern Europeans [58].
For instance, HLA-B*1502 is of low prevalence in Caucasians and hence, if it is a true suscept‐
ibility allele, a very large sample size is required in this population to detect a significant odds
ratio of sufficient power. In contrast, the allele frequency of HLA-A*3101 is 2-5% in Northern
Europeans [70] and the sample size required to demonstrate an association in a sufficiently
powered study is less than that for the HLA-B*1502 allele. The HLA-B*5801 allele, in contrast
to HLA-B*1502 is more evenly distributed among different racial groups [59] and hence,
associations, albeit weaker, have been demonstrated in other ethnic groups such as the
Southern Japanese [63] and in whites (OR 80 [34-157]) [68].
Another explanation is that HLA-B*1502, is a marker of a true disease contributing allele
through strong linkage disequilibrium, which varies between populations. In other words, the
same high-risk allele may have a different pattern of association with marker alleles and
therefore HLA-B*1502 is in strong linkage disequilibrium in the Han Chinese population, but
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not in a European population. It is also plausible is that SJS/TEN is a polygenic disorder, with
many susceptibility and protective alleles in genes involved in the pathogenesis of the disease.
Polymorphisms in the proapoptotic gene Fas-L [71], the toll-like receptor 3 gene [72], and in
the IL-4 receptor/IL-13 signalling pathway [73] have all been recently described in a Japanese
study. Such alleles may also vary in different populations.
The FDA and Health Canada have issued warnings for carbamazepine stating that persons
with ancestry in genetically at-risk populations should be screened for the presence of HLA-
B*1502 prior to initiating treatment [74]. Genetic screening for HLA-B*1502 in a high risk
population such as the Han Chinese has a 100% sensitivity and 97% specificity and its presence
confers a 7.7% positive predictive value for carbamazepine-induced SJS/TEN whereas its
absence has a 100% negative predictive value [58]. The odds ratio in test-positive Chinese
patients to test-negative patients of having carbamazepine-induced SJS/TEN is >3200. Al‐
though 3% of patients who are test-positive may never develop the disease, the serious and
life-threatening consequences of developing SJS/TEN and the availability of alternative drugs,
justifies its exclusion from these individuals. The lack of prevalence of HLA-B*1502 in non-
Asian populations may limit its cost effectiveness as a screening tool in these populations and
cannot be currently recommended. A recent study demonstrated the benefit of genetic
screening; in a Taiwanese population, screening for the HLA-B*1502 allele resulted in no cases
of SJS/TEN in 4501 patients who were negative for the allele [75]. The authors concluded that
this would have prevented 10 cases of SJS/TEN. Despite the FDA recommendations, screening
is not routinely performed partly because of the lack of availability of cost effective and rapid
methods of detection [76]. Susceptibility alleles can be identified by high resolution sequence
based HLA typing after a 20 ml sample of blood is collected in an ADC tube. However, this
highly specialized and relatively expensive diagnostic technique is limited to a small number
of laboratories that focus on transplantation medicine and may be limited by longer turn-
around times of up to 3-4 weeks. Many laboratories have now developed high resolution
genetic testing using a sequence-specific primer assay method for the detection of this allele
from samples collected in either 7-10 ml of whole blood (EDTA tube) or buccal swabs (provided
by the testing laboratory). The assay can be performed within 3-4 hours. Such a strategy is not
novel and has been very successful in virtually abolishing the incidence of HLA-B*5701-
associated abacavir hypersensitivity in HIV-infected patients [77]. Multiplexed PCRs can be
utilized to assess multiple alleles.
It is important to note that the HLA-B*1502 allele does not predispose to carbamazepine-
induced DIHS, maculopapular eruptions or other adverse reactions and continued vigilance
for the symptoms of SCAR needs to be maintained if treatment is commenced [61].
Currently, there is no recommendation for genetic screening prior to the commencement of
allopurinol therapy. Although such a strategy is plausible, studies are required to determine
the benefits of screening for the HLA*5801 allele in at risk populations.
4.6.2. Diseases
The EuroSCAR study showed that HIV infection conferred the highest risk of SJS/TEN;
multivariate relative risk (mvRR) 12 [2.4-59]. Other disease associations included collagen
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vascular disease mvRR 2.2 [0.9-5.0], recent malignancy mvRR 2.7 [1.3-5.7], recent radiotherapy
mvRR 2.1 [0.5-9.0], or acute infection in the past 4 weeks [1.2-2.3] [11].
4.6.3. Pharmacokinetics
The EuroSCAR study revealed an increased risk of SJS/TEN at higher doses of allopurinol;
adjusted odds ratio (OR) 36 [17-76] for doses ≥200 mg daily compared with an adjusted OR 3.0
[1.1-8.4] for doses <200 mg daily [78]. This study also revealed that the risk was mostly confined
to short-term use (≤8 weeks, unadjusted OR 261 [36-∞]). Allopurinol should be commenced at
a dose of 100 mg daily and increased by 100 mg increments until the desired serum uric acid
level is attained. Previous reports have shown that allopurinol is commenced at inappropriate
doses [79] and that higher doses are associated with an increased incidence of acute events [80].
It is likely that the rapid accumulation of the chemically reactive metabolite oxypurinol when
higher doses of allopurinol are commenced increases the risk of SJS/TEN [81],[82]. This drug
accumulation hypothesis is further supported by the 4.7 fold increased incidence of allopuri‐
nol-induced SCAR in renal insufficiency [83]. The established indications for allopurinol are
treatment of hyperuricemia associated with chronic gout, acute uric acid nephropathy,
recurrent uric acid stone formation, enzyme disorders of purine metabolism, and in the
management of tumour lysis. Allopurinol is not indicated in the majority of patients with
asymptomatic hyperuricemia [84]. However, allopurinol is inappropriately prescribed in up
to 86% of cases [85]-[87]. A comparison of allopurinol exposure between the SCAR (1989-1993)
and EuroSCAR (1997-2001) studies showed a 2-3 fold increase in exposure for both patients
and control subjects, which may be attributed to the increased prescribing of the drug for the
treatment of asymptomatic hyperuricemia. The authors of the EuroSCAR study postulate that
up to 48 of the 56 cases of allopurinol-induced SJS/TEN could have been prevented if the
treatment guidelines for prescribing allopurinol were followed.
Lamotrigine when commenced at high doses can also overwhelm the detoxifying capacity
resulting in an increased risk of SJS/TEN and DIHS [88]. The incidence has reduced signifi‐
cantly as a result of the now conventional practice of gradually titrating the dose [89]. Coad‐
ministration of certain drugs can predispose to SCAR by competition for the same enzyme-
binding site. Reactions to lamotrigine are more common when given in combination with
valproic acid as the addition of valproic acid inhibits the clearance of lamotrigine by competing
for glucoronic acid conjugation [90].
The role of slow acetylation phenotypes of N-acetyltransferase was thought to confer suscept‐
ibility of sulphonamide-induced SJS/TEN in two small studies [91],[92] but this needs confir‐
mation in larger studies.
4.7. Diagnosis
A presumptive diagnosis of SJS/TEN is made clinically and is confirmed with a skin biopsy
(Figs. 6 & 7). Early lesions demonstrate vacuolar alteration and scattered necrotic keratinocytes
in the epidermal layers at the level of the stratum spinosum and the basal cell layer. Later, full
thickness epidermal necrosis is evident, which eventuates in the formation of subepidermal
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bullae [93]. The mononuclear predominantly T cell dermal infiltrate is generally sparse but
dense infiltrates can also be present. Quinn et al, has shown an extensive infiltrate was
associated with a 71% mortality rate, a moderate infiltrate with a 53% mortality, and a sparse
infiltrate with a 27% mortality, respectively [94]. A fresh sample for direct immunofluoresence
(DIF) reveals an absence of immunoglobulin and complement deposition. The cornified layer
remains intact. Immunohistochemistry usually reveals a predominance of CD8 cells in the
epidermis and CD4 cells in the dermis. A fresh sample for direct immunofluoresence (DIF)
reveals an absence of immunoglobulin and complement deposition.
Figure 6. Low power view of a skin biopsy from a patient with SJS demonstrates separation of the epidermis from the
dermis at the level of the stratum spinosum and basal cell layer resulting in the formation of subepidermal bullae
(Hematoxylin-eosin, original magnification x40).
Cultures on blood, wounds and mucosal lesions should be performed to evaluate for super‐
infection. Serology may be performed for Mycoplasma pneumoniae if indicated.
A recent pilot study showed that serum granulysin levels may be raised early in the course of
disease but rapidly wanes with progression of disease [95]. Further studies are required to
determine whether this assay will prove to be a useful early diagnostic test for SJS/TEN.
4.8. Allergy testing
Skin tests and oral challenges are contraindicated in SJS/TEN because of the risk of inducing
a recurrence of disease. Patch testing has not been investigated extensively. The biggest cohort
comprised 22 patients and showed a poor sensitivity of only 9% [96]. Lymphocyte transfor‐
mation tests (LTTs) assesses the proliferation of the patient’s peripheral blood T cells cultured
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in the presence of a suspected drug for 6 days by measuring the incorporation of 3H-thymidine
during DNA synthesis. The result is expressed as a stimulation index, which is the ratio of cell
proliferation with antigen and without antigen. The sensitivity of LTTs in SJS/TEN is greatly
improved if the test is performed within 1 week of the onset of disease but becomes negative
by 6 weeks [97]. This may be attributed to loss of regulatory T cell function in the acute phase,
which is then restored upon recovery [55]. Recently, a new cytotoxicity assay combining the
measurement of expression of the degranulation marker, CD107a, using flow cytometry and
the release of the serine protease, granzyme B by Elispot after incubating the patient’s
peripheral blood mononuclear cells with the suspected drug for 3 days [98]. The test has very
good specificity with all of the 16 controls having a negative test and good sensitivity with 10
of the 12 patients having a positive result. One role of these in vitro tests is to determine the
culprit drug when more than one drug is suspected.
4.9. Differential Diagnosis
SJS/TEN is differentiated from other conditions on the basis of the acute onset of disease, the
presence of targetoid and vesiculobullous lesions, sloughing of the epidermis, severe mucosal
involvement, the histologic finding of full thickness epidermal necrosis, and a negative DIF.
In EM major, erosive mucous membrane involvement is present but in contrast to SJS, the
patient has typical target lesions mainly affecting the extremities and it is often induced by
acute or recurrent HSV infection. The clinical manifestations of drug-induced maculopapular
exanthems (MPE) are variable and often polymorphic and lesions may have a target-like
appearance. Fever may be present but mucosal involvement is absent. The histopathology
Figure 7. High power view of a skin biopsy from a patient with SJS shows necrosis of keratinocytes, and vacuolar de‐
generation of the basal cell layer. A sparse lymphocytic infiltrate is present at the dermoepidermal junction and dis‐
plays satellitosis or clustering around dying basal cells (Hematoxylin-eosin, original magnification x200).
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typically shows an interface dermatitis with hydropic degeneration of the basal cell layer [99].
Some exanthems may progress to more severe reactions such as SJS/TEN or DIHS. Generalized
bullous fixed drug eruption (GBFDE) features large brownish violaceous patches upon which
flaccid blisters arise. These blisters affect only a small percentage of the TBSA. Mucosal
involvement is rare and fever is absent. Most patients report a history of a similar local reaction
or fixed drug eruption [100].
Staphylococcal scalded skin syndrome (SSSS) usually affects children under the age of 5 years
and patients present with fever, erythema and painful skin, followed by blistering, which is
typically accentuated in areas of friction and around orifices [101]. SSSS is caused by the
systemic distribution of epidermolytic toxins produced by certain strains of Staphylococci.
These toxins cause separation at the level of the stratum granulosum, the upper layer of the
epidermis, resulting in very superficial detachment of the skin and blistering[102]. Mucous
membrane involvement is rare. The condition usually but not always follows local or systemic
staphylococcal infection [103]. Adults are less susceptible as improved renal function allows
for better clearance of the toxins. However SSSS has been described in adults who are immu‐
nosuppressed or in renal failure [101]. Toxic shock syndrome (TSS) is caused by elaboration
of toxins produced by Staphylococcus aureus and Streptococcus pyogenes that act as superanti‐
gens, which bind to the variable regions of β chains of antigen receptors on subsets of T cells
and cross-link them to the MHC molecules of antigen-presenting cells [104]. This results in
activation of large numbers of T cells (5-30%) and the massive release of cytokines including
IL-2, TNF, lymphotoxin and IL-1β. TSS is characterised by fever, diffuse red macular rash,
hypotension and involvement of ≥3 organs: renal failure, hepatitis, thrombocytopenia,
encephalopathy, mucous membrane hyperemia, gastrointestinal involvement with vomiting
and diarhhoea. Desquamation occurs after 1-2 weeks and predominantly affects the palms and
soles. Approximately 50% of cases are menstrually related due to the prolonged application
of absorbent tampons. Notably, 50% of cases of TSS are not associated with menstruation. Non-
menstrual cases of TSS usually complicate the use of barrier contraceptives, surgical and
postpartum wound infections, burns, cutaneous lesions, osteomyelitis, and arthritis. Although
most cases of TSS occur in women, about 25% of non-menstrual cases occur in men.
Autoimmune bullous diseases need to be considered in the differential diagnosis of SJS/
TEN.  These  conditions,  in  contrast  to  SJS/TEN,  usually  have  a  chronic  course  and  are
characterized by acantholysis on histopathology and immunoglobulin deposition on DIF.
Drug-induced linear IgA bullous dermatosis can produce an acute extensive eruption of
target-like  lesions,  pruritic  urticarial  plaques  and  tense  bullae  on  the  trunk  and  limbs
[105]. Vancomycin is the most commonly implicated drug. In contrast to SJS, mucosal le‐
sions are rare and DIF shows linear deposition of IgA at the basement membrane zone.
Paraneoplastic pemphigus (PNP) is a chronic disease characterized by severe and intract‐
able  oral  mucositis  and  a  generalized  polymorphous  blistering  eruption  in  association
with an occult or overt malignancy, especially, lymphoma and Castleman’s disease [106],
[107].  Conjunctivitis  is  common and respiratory and gastrointestinal surfaces may be in‐
volved. DIF shows deposition of IgG and complement (C3) within the epidermal intercel‐
lular  spaces  and along the epidermal  basement  membrane.  Drug-induced pemphigus is
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usually triggered by thiol drugs in genetically susceptible individuals [108]. These drugs,
such  as  penicillamine,  captopril  and  enalapril,  directly  interact  with  the  epidermis  and
cause acantholysis and a superficial blistering eruption with crusts and erosions without
mucosal involvement resembling pemphigus foliaceus (PF) [109]. However, in contrast to
PF, which is mediated by antibodies against desmoglein-3, DIF may be negative in drug-
induced pemphigus.  Non-thiol  drugs  can  cause  disease  indistinguishable  from pemphi‐
gus  vulgaris  (PV).  These  cases  of  drug-triggered  pemphigus,  like  PV  are  chronic  with
autoantibodies  formed  against  desmoglein-3  [110].  Hence  a  flaccid  blistering  eruption
with mucosal involvement occurs,  and DIF shows IgG and C3 deposition in the epider‐
mal intercellular spaces. Bullous pemphigoid (BP) is a chronic disease that is typified by
a  tense  bullous  eruption  that  primarily  affects  individuals  in  the  fifth  through  seventh
decades of life. Drugs, especially diuretics such as furosemide and spironolactone, can in‐
duce BP [111]  and should be considered when the condition occurs  in  a  young patient
and the course is more abrupt [112]. Unlike in SJS/TEN, fever is absent, mucosal lesions
are  usually  absent,  and  DIF  reveals  IgG  and  C3  linear  deposition  along  the  epidermal
basement membrane [113].
Acute graft versus host disease (AGVHD) shares many of the same clinical, pathologic and
immunologic features as SJS/TEN. Both conditions are mediated by cytotoxic T cells, which
results in epidermal necrosis and keratinolysis [114],[115]. Furthermore, bone marrow
transplantation (BMT) patients receive medications that can trigger SJS/TEN. AGVHD
generally occurs 4 weeks after stem cell transplantation. Patients describe a sensation of skin
pain and itching followed by a morbilliform rash that in severe cases becomes generalized with
diffuse areas of epidermal necrosis [116]. Mucositis is usually present. AGVHD frequently
begins acrally and spreads proximally in contrast to TEN, which begins on the trunk and
spreads distally. Also, the early exanthem of AGVHD has a folliculocentric distribution [117].
AGEP is characterized by fever and as the disease progresses, widespread erosions mimicking
SJS/TEN may be evident [118]. Mucous membrane involvement is unusual and if present is
mild.
SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis; EM, erythema multiforme;
MPE, maculopapular exanthem; GBFDE, generalized bullous fixed drug eruption; SSSS,
staphylococcal scalded skin syndrome; TSS, toxic shock syndrome; PNP, paraneoplastic
pemphigus; AGVHD, acute graft versus host disease; AGEP, acute generalized exanthematous
pustulosis
4.10. Treatment
4.10.1. Supportive care
Immediate discontinuation of the culprit drug is mandatory to reduce mortality [119]. As the
management of TEN is similar to that of extensive burns, a transfer to a burns unit reduces
morbidity and mortality. The largest trial showed a mortality rate of 29.8% after transfer to a
burns unit compared to 51.4% (p <.05) after 7 days [120]. The unit has expertise in providing
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Bullous disease Fever Mucositis Rash DIF Onset Other notable
features
SJS/TEN + + Erythroderma
Targetoid lesions
Vesicles, bullae
Erosions, detachment
- Acute Starts on trunk,
proximal upper limbs
and face and then
spreads
EM Major + + Acral
Target lesions
- Acute HSV-induced
recurrences
Drug-induced MPE +/- - Variable
Pleomorphic
- Acute May progress to SJS or
DIHS
GBFDE - - Brown patches
Large bullae
- Acute Antecedent local
reaction
Small % TBSA
SSSS + - Erythroderma
Skin tenderness
Periorificial crusting
- Acute Children under 5
Adults with chronic
renal failure and on
immunosuppressive
therapy
TSS + + Diffuse red macular
rash
Desquamation of
palms and soles
- Acute Hypotension
Multiple organ failure
Drug-induced
linear IgA dermatosis
- - Tense bullae + Acute Vancomycin
Pruritus
PNP - + Polymorphous
Bullae
+ Gradual
Drug-induced
pemphigus
- - Erosions
Crusts
+ Gradual Thiol drugs
Drug-triggered
pemphigus
- + Mucosal erosions
Flaccid bullae
+ Gradual Non-thiol drugs
AGVHD + + Morbilliform rash
Bullae
Erosions, detachment
- Acute Starts acrally and then
spreads
AGEP + +/- Small nonfollicular
pustules
Erythroderma
- Acute
Table 2. The differential diagnosis of SJS/TEN
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analgesia, maintaining fluid and electrolyte balance and preventing and treating superinfec‐
tion. It has been recently noted that in contrast to burns, TEN affects the epidermis and hence
fluid and electrolyte requirements are less than for burns of the same extent [121]; initial
administration of 2 ml/kg/%TBSA is usually sufficient [122]. Additional nutritional require‐
ments result from loss of nitrogen and energy from the wound exudate, the hypermetabolic
response of TEN and sepsis and the promotion of wound healing. However, these require‐
ments may lower than in burns, with one study in the paediatric population suggesting that
that patients with TENS require 22% fewer calories per day than patients with burns. A formula
was subsequently developed: calorie requirement = baseline weight (kg) x 24.6 + wound size
(%TBSA) x 4.1 + 940 [123]. Enteral or total parenteral nutrition should be considered in patients
unable to ingest food. Nasogastric feeding should be cautiously initiated because of gastroin‐
testinal involvement from TEN and the difficulties in placing a nasogastric tube in the presence
of a oropharyngeal involvement [124]. Room temperature should be adjusted to 30-32ºC or
heat-air body warmers should be used to prevent excessive caloric expenditure due to
epidermal loss [25].
The optimal approach to wound management has not been determined and will therefore vary
between specialty units. The contrasting measures of surgical debridement with whirlpool
therapy to remove necrotic epidermis, and anti-shear wound care [125], in which detached
skin is left in situ to act as a biological dressing [126], both have equivalent rates of re-
epithelialization and survival. Non-adherent nanocrystalline-containing gauzes are being
increasingly used because of their broad antimicrobial effects [127],[128]. This obviates the
need for topical silver sulphadiazine because of the strong association between sulphonamides
and SJS/TEN. There is also a trend in the use of biosynthetic skin substitutes in place of porcine
xenograft and human allograft cadaveric skin because of reduced pain and improved mobili‐
zation in elderly patients [129].
Prophylactic antibiotics are not advised as they predispose to the emergence of resistant
organisms [121]. Hence, repeated cultures of the skin, blood and other sites guide the need for
antibiotic therapy. Sterile handling and reverse-isolation procedures are essential in the
prevention of nosocomial infection [130].
Ophthalmologic consultation is mandatory in SJS/TEN and the combination of aggressive
lubrication, topical antibiotics, topical corticosteroids, and lysis of adhesions with a glass
rod is  implemented immediately  but  has  only  a  modest  effect  on  the  long term ocular
complications.  Recently,  the  application  of  amniotic  membranes  has  proved effective  in
preserving visual acuity and an intact ocular surface [37]. The benefit may be derived from
creating a physical barrier between inflamed and denuded mucosal surfaces that minimiz‐
es  the  formation  of  adhesions.  The  membrane  may  also  have  antiinflammatory  and
antifibrotic effects [131].
Other supportive measures include hygienic mouthwashes and topical oral anaesthetics, and
monitoring for urinary retention.
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4.10.2. Corticosteroids
The role of corticosteroids in the treatment of SJS/TEN is controversial. Corticosteroids given
48 hours or more prior to admission are associated with an increase incidence of infection,
length of hospital admission, and mortality in children and adults [132]-[134]. A study in 1986
of 30 patients with TEN with an average TBSA involvement > 80% were equally divided into
those receiving supportive care alone and those receiving dexamethasone at varying doses
[135]. Although the incidence of sepsis was not significant different between the groups, the
survival following onset of sepsis was less in the corticosteroid treated group. The use of
corticosteroids doubled the rate of mortality (66% versus 33%). Corticosteroids do not prevent
SJS/TEN from occurring and have no effect on arresting disease progression [136],[137]. A
retrospective analysis of 281 patients from the EuroSCAR study found no benefit from
corticosteroids or IVIg compared to supportive care alone.
The poor outcomes may have resulted from inadequate doses and the delay in the initiation
of corticosteroid therapy. In a prospective study of 16 children with SJS in 1997, 10 received
methylprednisolone (4 mg/kg/daily) within 3 days of the onset of rash whilst 6 received
supportive care only; corticosteroids were associated with decreased length of fever and
duration of skin eruption [138]. The use of pulsed IV corticosteroids has been shown in
retrospective reviews to reduce mortality [139]-[141]. The initiation of IV methylprednisolone
500-1000 mg/daily for 3-4 days may also prevent ocular complications of cicatrization and
preservation of visual acuity [142]. The benefits of early pulsed therapy with IV corticosteroids
need to be further evaluated in randomized control trials.
The current level of evidence suggests that high dose corticosteroids may be beneficial if
commenced early in the course of disease with vigilant monitoring for emergence of infection.
However, no definitive conclusion can be drawn from this current level of evidence and
prospective trials with well defined protocols are required to define the role of corticosteroids
in the treatment of SJS/TEN.
4.10.3. Intravenous Immunoglobulin (IVIg)
The rationale for the use of IVIg was based on its ability in vitro to block Fas and subsequently
FasL-mediated apoptosis of keratinocytes [51]. The beneficial role of IVIg in SJS/TEN has been
demonstrated in retrospective studies. The largest such study to date comprised 48 patients
with TEN with a 44.8% mean TBSA recruited from centres across Europe and the United States.
Treatment with IVIg resulted in a more rapid cessation of epidermal detachment and a survival
rate of 88%. The authors subsequently recommended a dose of 1 g/kg/daily for 3 days [143].
Studies have also demonstrated benefit when investigators have compared the rates of
mortality following the use of IVIg with the pre-treatment estimate using SCORTEN. For
example, Campione et al, found that 400 mg/kg/daily for 5 days of IVIg resulted in a mortality
rate of 10%, significantly lower that the 35% predicted using SCORTEN [144]. Metry et al,
showed that the benefit of IVIg extended to the paediatric population [145].
In 2006, a retrospective study found that the use of IVIg at a total dose of 2.8 g/kg/daily in 23
patients resulted in a marked difference in mortality compared to 8 patients who received
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supportive therapy alone despite the absence of a difference in SCORTEN between the two
groups. The mortality rate was 26% in the patient group receiving IVIg and 75% in the group
receiving supportive care only. This difference, however, was not statistically significant. A
study by Yang et al, showed a lower than predicted mortality rate for patients given IVIg and
corticosteroids and a higher than expected mortality rate for those receiving corticosteroids
alone. This difference was not statistically significant [146].
Despite the initial preponderance of evidence favouring the use of IVIG in SJS/TEN, a few
published reports have not demonstrated any benefit. Most of these studies comparing the use
of IVIg with supportive care alone used doses less than the recommended 2-3 g/kg [147]-[150].
The largest restrospective analysis on the use of IVIg derived from the EuroSCAR study and
published in 2008 included 109 patients with TEN, 136 with SJS/TEN overlap, and 134 with
SJS found that IVIg administered at a dose of 1.9 g/kg conferred an OR of 1.4 when compared
to the use of supportive measures alone. This study involved the use of lower than recom‐
mended doses of IVIg and the patients from the IVIg group tended to have a greater TBSA
involvement [151]. A controlled observational study in an intensive care unit in a French
dermatology department of 34 patients who presented at a mean of 4.3 days after the onset of
TEN revealed a higher mortality rate than that predicted by SCORTEN when 2g/kg of IVIg
was administered within 2 days of admission [85].
Randomized control studies are required using sufficient doses of IVIg to characterize its
benefit in not only reducing mortality but also arresting the rate of progression and hastening
the rate of re-epithelialization. However, the evidence thus far, is not robust as an adjunctive
immunomodulatory therapy in the treatment of SJS/TEN.
4.10.4. C yclosporine
Cyclosporine inhibits CD8 activation and subsequent release of granulysin, granzyme and
perforin as well as inhibiting the proapoptotic effect of NF-ĸB. Several case and case series
reports have shown arrest of disease progression and shorter time to re-epithelialization with
doses varying from 3-10 mg/kg/daily for a period ranging from 8 days to several weeks [152]
[153]-[161]. The study by Arevalo et al, showed that outcomes for 10 patients treated with
cyclosporin was superior to 6 patients treated with cyclophosphamide and corticosteroids with
respect to re-epithelialization, disease progression and death [157]. However, randomized
control studies are required to better define its benefits, the appropriate dose and duration of
therapy. Furthermore, no studies have been published to date evaluating the efficacy of using
both IVIg and cyclosporine but may be worthwhile considering as different pathways involved
in the pathogenesis of SJS/TEN are targeted.
4.10.5. Plasmapheresis
Plasmapheresis (PE) has been reported to be beneficial in several case reports and series in
patients with TEN based on the principle that the drug, drug metabolite or cytotoxic mediator
is removed from the circulation [162]-[165]. One report from Sweden showed no benefit from
PE in eight patients compared with patients from other studies who received similar support
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care but without PE [166]. There is insufficient evidence at this stage to support the use of PE
in preference to other adjunctive measures.
4.10.6. Anti-TNF therapy
TNF is thought to be upregulated in TEN and immunohistochemistry has demonstrated
increased levels of TNF from 23 patients as compared with controls [167]. Thalidomide, a
potent inhibitor of TNF, was found in a double blinded randomized placebo controlled trial
to be lethal in 10 of 12 patients compared with 3 of 10 control subjects. The exact mechanism
underlying these fatalities is unknown but the drug is firmly contraindicated in SJS/TEN.
Infliximab and eternecept has been shown to be beneficial in a small number of case reports
[168]-[173]. The drug was usually administered late in the course of disease and therefore its
benefit is not clear and requires case-control studies to further elucidate its role.
4.10.7. N-acetylcysteine
Strategies have been explored to overcome the diminished detoxifying capacity of abnormal
inherent metabolic pathways evident in a proportion of patients with SJS/TEN. Administration
of N-acetylcysteine enhances the oxidant buffering capacity of glutathione, which enhances
the detoxification of a range of drugs, as well as inhibiting NF-ĸB. Two case reports have shown
a beneficial response but larger studies are clearly required before it is readily applied in clinical
practice [174],[175].
4.10.8. Restricted use of related medications
In addition to the restricted use of the same medication, structurally similar drugs should also
be avoided. The aromatic anticonvulsants carbamazepine, phenytoin and phenobarbitol cross
react with one another. Cross reactivity resulting in SJS/TEN can also occur across different
classes of beta-lactam antibiotics, such as penicillins, cephalosporins and carbapenems [176].
Administration of a structurally related drug can also result in different reactions. One case
report described a patient with ceftriaxone-induced TEN who developed immediate anaphy‐
laxis following the administration of piperacillin/tazobactam [177].
The risk of SJS/TEN with structurally distinct agents within the same class of drug is less clear.
For example, the cross reactivity between a priopionic acid NSAID and an enolic acid NSAID
is unknown. The safest practice is to restrict all NSAIDs following NSAID-induced SJS/TEN.
5. Drug induced hypersensitivity syndrome
5.1. Nosology
The term hypersensitivity syndrome has been used for decades to describe a cutaneous drug
reaction accompanied by involvement of internal organs. In 1938, Merritt and Putnam
described a toxic reaction to phenytoin characterized by exfoliative dermatitis, fever and
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eosinophilia [178]. This was distinguished from those patients who developed a mild,
morbilliform rash. Chaiken et al coined the term Dilantin hypersensitivity in 1950 to further
characterize the systemic reaction described by Merritt and Putnam to also include lympha‐
denopathy and multivisceral involvement [179]. Saltzein in 1959 described a drug-induced
lymphoma characterized by lymphadenopathy and diffuse skin nodules and plaques without
internal organ involvement. [180]. The anticonvulsant hypersensitivity syndrome was named
in 1988 by Shear and Spielberg to refer the similar cutaneous and systemic manifestations of
idiosyncratic reactions to a range of anticonvulsant medications including phenytoin, pheno‐
barbitol and carbamazepine [181]. In 1996, Bocquet et al introduced the term drug reaction
with eosinophilia and systemic symptoms (DRESS) to distinguish it from drug-induced
pseudolymphoma and other drug reactions that are not associated with eosinophilia [182].
Finally, Shiohara et al proposed the term drug induced hypersensitivity syndrome (DIHS) to
include patients who may not have marked eosinophilia but have other evidence of leukocyte
abnormalities, internal organ involvement and evidence of HHV-6 reactivation [183],[184].
5.2. Epidemiology
The incidence of DIHS is estimated to be between 1 in 1000 and 1 in 10000 to phenytoin [185].
The true incidence remains to be determined because of the variable presentations and the lack
of universally accepted criteria. The JSCAR and RegiSCAR studies will provide more accurate
reporting on the basis of stringent criteria. Preliminary data from the RegiSCAR study suggests
that it affects males and females equally with a mean age of 47.4 years (range 3-84 years) [186].
5.3. Etiology and clinical features
Various diagnostic criteria have been proposed. Bocquet et al stipulated the presence of (1)
cutaneous drug eruption; (2) hematologic abnormalities including eosinophilia greater than
1.5 x109/L or the presence of atypical lymphocytes; and (3) systemic involvement including
adenopathy greater than 2 cm in diameter, hepatitis (liver transaminase values >2 normal),
interstitial nephritis, interstitial pneumonia, or carditis.
Kardaun et al developed a scoring system to validate the diagnosis [187].
The potential role of HHV-6 in the pathogenesis of DIHS was incorporated into the criteria for
DIHS by the JSCAR group [188]: (1) maculopapular rash developing more than 3 weeks after
starting a limited number of drugs; (2) prolonged clinical symptoms 2 weeks after discontin‐
uation of the causative drug; (3) fever greater than 38 C; (4) liver abnormalities (eg, ALT levels
>100 U/L); (5) leukocyte abnormalities such as leukocytosis (>11 x 109/L), atypical lymphocy‐
tosis (>5%), and/or eosinophilia (>1.5 109/L); (6) lymphadenopathy; and (7) HHV-6 reactiva‐
tion. Diagnosis of typical DIHS requires the presence of all 7 criteria. If criteria 1-5 are present
only, then a diagnosis of atypical DIHS is made.
The syndrome typically begins 3 weeks to 3months after commencing therapy with a limited
number of drugs of which the most prominent ones are listed below.
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High-grade fever (38-40°C) is usually the first symptom followed by the development of facial
oedema (Fig. 8), often with pinhead-sized pustules, and an erythroderma with edematous,
follicular and purpuric lesions (Fig. 9). An exfoliative dermatitis often eventuates especially if
Assessment/Score -1 0 1 2 min max
Fever ≥38.5oC n y -1 0
Enlarged lymph nodes n/u y 0 1
Eosinophilia
Eosinophilia n/u 700-1499/μL "/>1500/μL 0 2
Eosinophilia if WCC<4000/μL 10-19.9% ≥20%
Atyical lymphocytes n/u y 0 1
Skin involvement
Skin rash extent (%TBSA) n/u "/>50%
Skin rash suggestive of DRESS n u y -2 2
Histology suggestive of DRESS n y/u
Organ involvement *
Liver
Kidney
Lung n/u "/>1 y ≥2 y 0 2
Heart
Pancreas
Other organ
Resolution ≥15 days n y -1 0
Serology/PCR
Hepatitis A,B,C
EBV,CMV
Mycoplasma,Chlamydia
ANA
Blood culture
If non +ve and ≥3 -ve n 0 1
Total -4 9
y, yes; n, no.
*After exclusion of other causes: 0, no organ involvement; 1, 1 organ involved; 2, ≥ 2 organs involved.
Final score: <2, excluded; 2-3, possible; 4-5, probable; >5, definite.
Table 3. Diagnostic validation score for DRESS
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Carbamazepine
Phenytoin
Phenobarbitol
Zonisamide
Lamotrigine
Allopurinol
Dapsone
Sulphasalazine
Mexiletine
Minocycline
Strontium ranelate
Abacavir
Table 4. The main causative drugs of DIHS
Figure 8. Facial erythema and edema with labial ulceration in a young woman with DIHS/DRESS.
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the causative drug is not withdrawn (Fig. 10). Cheilitis (Fig. 8), pharyngeal erythema and oral
ulceration may occur but severe stomatitis is not present. Tender lymphadenopathy in more
than two sites and bilateral swelling of salivary glands with xerostomia is evident early in the
course of disease. Hepatosplenomegaly is a common finding. Leukocytosis with atypical
lymphocytes and eosinophilia (60-70% of cases) is a prominent feature of this syndrome
although the eosinophilia may not be observed for 1-2 weeks. Thrombocytopenia and anemia
may also be present. Hypogammaglobulinema is noted at the onset of disease with the nadir
occurring several days after the withdrawal of the causative drug [189]. An overshoot in the
IgG level occurs 1-2 weeks after the nadir before returning to normal on full recovery. Internal
organ involvement is listed in table 5.
Figure 9. Maculopapular eruption and erythroderma of the trunk in DIHS.
The onset of symptoms is variable with patients developing 2-3 symptomatic features followed
by stepwise development of other manifestations. In most cases, withdrawal of the drug is not
followed by rapid resolution of symptoms. Many patients may continue to deteriorate and
show periodic relapses for weeks after the withdrawal of the causative drug.
Several reports have described the occurrence of autoantibody formation and autoimmune
diseases up to 4 years after the acute resolution of DIHS/DRESS [201] and these include type
1 diabetes mellitus [202], autoimmune thyroid disease [203], scleroderma GVHD [204], SLE
[205], and bullous pemphigoid [206]. One of the likely explanations for the occurrence of
autoimmune disease is the depletion of regulatory T cells upon recovery of disease.
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Abacavir, an HIV nucleoside analogue reverse transcriptase inhibitor causes a potentially life-
threatening hypersensitivity syndrome in approximately 5-8% of recipients within 6 weeks of
therapy [207],[208]. The clinical and laboratory features of this syndrome differs from typical
cases of DIHS/DRESS in that there is a predilection for the gastrointestinal system with nausea,
abdominal pain, diarrhoea, and the respiratory tract with cough, pharyngitis and shortness of
Figure 10. Exfoliative dermatitis involving the hand in a young woman with DIHS/DRESS who had continued to ingest
the culprit drug for 4 weeks when this image was taken.
Manifestation Comments
Hepatitis (mixed hepatocellular and cholestatic) 71%[190]
Interstitial nephritis 11%, frequent with Allopurinol-induced
DIHS[191]
Pneumonitis/pleuritis Common in minocycline[192] and abacavir[193]
induced DIHS
Myocarditis Occurs at onset or 40 days after onset of
DIHS[194]
Limbic encephalitis 2-4 weeks after onset of DIHS, HHV-6
reactivation in CSF[195]
May be assoiciated with SiADH[196]
CMV Gastrointestinal ulceration with bleeding 4-5 weeks after onset of DIHS[197]
Haemaophagocytic syndrome Rare, occurs 2 weeks after onset of disease[198]
Parotid gland enlargement Rare[199]
Pancreatitis Rare[200]
Table 5. Internal organ involvement in DIHS
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breath. Headache, myalgia and/or arthralgia may also be present. Eosinophilia is present in <
10% of cases and liver function test abnormalities are detected in < 20% of cases [209]. Also,
the manifestations resolve within 72 hours rather than having a protracted relapsing course
and the role of herpetic viruses in this condition is unknown.
5.4. Differential diagnosis
Viral infections such as EBV, CMV, and measles can be distinguished by the absence of
eosinophilia, hypogammaglobulinemia, and supportive serology. In children, DIHS/DRESS is
differentiated from Kawasaki’s disease by the absence of a bulbar conjunctivitis, strawberry
tongue, coronary aneurysms, hypoalbuminemia and thrombocytosis. Serum sickness is
characterized by urticarial lesions and the absence of internal organ involvement. Atopic
erythroderma with bacterial infection does not usually involve hepatitis or nephritis. Drug-
induced pseudolymphoma from carbamazepine or phenytoin is distinguished from DIHS/
DRESS by the absence of internal organ involvement and the prompt resolution of symptoms
when the drug is withdrawn. Cutaneous B and T cell lymphomas have an indolent course and
characteristic histopathology.
5.5. Pathology
The histopathology of DIHS/DRESS is relatively non-specific and consists of a lymphocytic
infiltrate that is superficial, perivascular, dense and diffuse. Eosinophils may be present but is
often absent. The presence of loose rather than discrete granulomatous aggregates of histio‐
cytes have been recently reported (Figs. 11, 12) [210]. This may be due to continued exposure
to the culprit drug after the onset of DIHS/DRESS. Granuloma formation occurs as a conse‐
quence of a delayed-type hypersensitivity (type IV) reaction, the classic example of which is
the tuberculin reaction where a cutaneous granuloma is induced after injection of purified
protein derivative in a previously sensitized individual. The expansion of CD4 cells and the
secretion of IFN-γ and other Th-1 cytokines result in the recruitment of macrophages. Sus‐
tained drug exposure and the persistence of cytokine release promote differentiation of
macrophages into epithelioid cells, which secrete TNF promoting their fusion to form multi‐
nucleate giant cells and granulomas. HHV-6 and DNA from other herpes viruses may be
detected in skin lesions by PCR or in situ hybridization [183].
5.6. Drug allergy testing
5.6.1. Patch tests
Santiago et al recently studied the utility of patch testing in DIHS/DRESS and found a positive
reaction in 32% of the 56 patients. Patch testing was performed between 6 weeks and 6 months
after healing of the lesion and at least one month after corticosteroids were ceased. They found
that 76% of the 17 patients with carbamazepine-induced DIHS/DRESS were patch test positive
but none of the 19 allopurinol-sensitive patients were positive to allopurinol and its metabolite,
oxypurinol. No systemic reactions occurred during or after testing [211]. Hence patch testing
may prove useful once the reagent and timing of such testing is optimized. Patch testing has,
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Figure 11. Low power view of a skin biopsy from a patient with DIHS demonstrating the superficial dermal nature and
perivascular distribution of the inflammatory infiltrate with acanthosis and hyperkeratosis of the epidermis (Hematox‐
ylin-eosin, original magnification x40).
Figure 12. High power view of a skin biopsy from a patient with DIHS demonstrates granulomatous inflammation
with prominent, but relatively loosely aggregated histiocytes, mixed with lymphocytes. Eosinophils are absent (Hema‐
toxylin-eosin, original magnification x200).
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however, proven to be very useful in confirming suspected cases for abacavir hypersensitivity
with a higher degree of specificity than can be confirmed clinically [212].
5.6.2. Lymphocyte transformation tests(LTTs)
LTTs are usually negative up to 3 weeks after the onset of DIHS/DRESS but most patients are
positive at 5-7 weeks and have persistent responses even at 1 year. Treatment with corticoste‐
roids did not affect the results [97]. One possible explanation for the negative LTT result during
the acute phase of DIHS is the expansion T regulatory cells with a naïve phenotype
(CD4CD25FoxP3), which then are depleted by apoptosis during the recovery phase. These
regulatory T cells are capable of suppressing proliferation of memory T cells in LTTs [55].
5.7. Pathogenesis
The pathogenesis of DIHS/DRESS is still to be fully elucidated. The precise role of HHV-6 in
DIHS is unclear. The initiating event may be the reactivation of one or more herpetic viruses,
which is clinically unapparent. Virus-stimulated T cells may then cross react with drug-derived
hapten-protein conjugates that are presented by dendritic cells to naïve antigen-specific CD4
T-cells with the subsequent differentiation into effector/memory CD4 cells. These dendritic
cells may also activate CD8 T-cells by cross-presentation. The expansion of effector CD4 T-cells
with their production of IFN-γ and other cytokines results in recruitment and activation of
macrophages. Failure to eradicate the antigenic stimulus, in this instance due to the continued
ingestion of the drug, causes persistent cytokine release and promotes differentiation of
macrophages into epithelioid cells, which secrete large amounts of TNF promoting their fusion
to form multinucleate giant cells [210]. Analogous to that observed in GVHD, longitudinal
real-time PCR analyses of viral loads in blood samples drawn from patients with DIHS show
that various herpetic viruses are sequentially activated as a result of massive T cell stimulation,
B cell loss and hypogammaglobulinemia [213]; Activation of Epstein-Barr virus or HHV-6
extends to the sequential activation of HHV-7, cytomegalovirus and varicella-zoster virus
[189]. The frequent deterioration or several exacerbations that occur despite continuation of
the drug may at least be partly explained by sequential reactivation of herpetic viruses and
the immune response to viral replication. An alternative explanation is that drug specific T
cells are activated resulting in reactivation of the viral genome and sequential reactivation of
herpes viruses.
Genetic susceptibility may also play a role as all patients with allopurinol-induced DIHS in a
Han Chinese population harboured the HLA-B*5801 allele compared with 15% of control
subjects [67]. Recently, an association was described between HLA-A*3101 and DIHS in
Northern Europeans; OR 12.41 [1.27-121.03] [64] and in the Japanese; OR 9.5 [4.6–19.5] [65]. In
a Western Australian HIV Cohort Study, HLA-B*5701 was present in 14 (78%) of the 18 patients
with abacavir hypersensitivity, and in four (2%) of the 167 abacavir tolerant patients; OR 117
[29-481] [193]. There is a discrepancy in the association of HLA-B*5701 and abacavir hyper‐
sensitivity across various racial groups The association was confirmed in a separate cohort of
HIV-infected white Americans and was also found to confer susceptibility in Hispanics but
not in blacks [214]. No association was found in a cohort of Korean patients [215]. Hence
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screening for HLA-B*5701 is not useful in predicting sensitivity in all patients. The racial
variation may be partly explained by the differences in MHC haplotypes across different racial
groups. The Caucasian 57.1 ancestral haplotype, which confers susceptibility to abacavir
hypersensitivity possibly as a result of strong linkage disequilibrium with other candidate
genetic factors such as cellular chaperones (e.g. heat shock proteins), inflammatory cytokines
(e.g. TNF), and proteins involved in the stress response (e.g. MHC class I chain-related genes,
MIC-A and MIC-B). African populations do not demonstrate this haplotype [216]. However,
in a recent study by Saag et al, all 42 white patients with immunologically confirmed (i.e.
positive patch tests) hypersensitivity reactions were HLA-B*5701 positive (sensitivity 100%,
OR 1945 [110-34,352]) but in addition all 5 black patients with immunologically confirmed
hypersensitivity reactions were HLA-B*5701 positive (sensitivity 100%, OR 900 [ 38-21,045].
Screening for the HLA-B*5701 has eliminated immunologically confirmed cases of abacavir
hypersensitivity [217].
5.8. Treatment
Early recognition of the syndrome with cessation of the causative drug is essential in improving
patient outcomes. No randomized controlled trials have been conducted to determine the
appropriate adjunctive therapy for DIHS/DRESS. Oral corticosteroids at 1 mg/kg/daily is
commenced and tapered over at least 6-8 weeks to prevent relapse of various cutaneous and
visceral manifestations of the syndrome. If symptoms deteriorate despite corticosteroid
therapy then IVIg [218],[219], plasma exchange [220], rituximab, gangciclovir or a combination
of these modalities [221] can be considered.
Recently, the French Society of Dermatology formulated guidelines on the management of
DIHS/DRESS [133]:
1. Absence of signs of severity: topical corticosteroids, emollients and H1-antihistamines.
2. Presence of signs of severity (transaminases >5 times normal, renal impairment, pneu‐
monia, hemophagocytosis, cardiac involvement): prednisone 1 mg/kg/day.
3. Life-threatening signs: (hemophagocytosis with bone marrow failure, encephalitis, severe
hepatitis, renal failure, respiratory failure): prednisone and IVIg 2 g/kg over 5 days.
4. Presence of signs of severity with confirmation of major viral reactivation: prednisone and
gangciclovir and/or IVIg.
6. Acute generalized exanthematous pustulosis
6.1. Nosology
In 1980, Beylot et al [222] introduced the term acute generalized exanthematous pustulosis
(AGEP) to describe acute pustular reactions with distinct clinical and histological features
thereby differentiating it from pustular psoriasis.
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6.2. Epidemiology
AGEP is rare with an incidence of 1-5 cases per million per year [223]. The EuroSCAR study
comprising 97 validated cases of AGEP recruited from Austria, France, Israel, Italy and the
Netherlands, revealed a mean age (±SD) of 56 (±21) years and a female preponderance with a
male/female ratio of 0.8 [18]. The predominance in women was shown to be even greater in
case series reports from Taiwan (68.7% of 16 cases) [224], and Israel (76.9% of 13 cases) [225].
AGEP has been reported in children, with the largest pediatric series of 20 cases from China
[226].
6.3. Clinical features
The clinical manifestations are characterized by fever and a pruritic or burning edematous
erythema (Figs. 13 A&B) followed by the rapid appearance of dozens of small (< 5 mm) non-
follicular sterile pustules (Fig. 14). The skin lesions are often accentuated in the intertriginous
areas (Fig. 13 C). There is usually an accompanying marked neutrophilia (7 x 109/L) and in a
third of cases, a mild eosinophilia. A mild non-erosive mucous membrane involvement occurs
in 20% of cases. Internal organ involvement is uncommon and usually is confined to a slight
reduction in creatinine clearance and mild elevation of aminotransferases.
The clinical course is characterized by spontaneous resolution of skin and systemic manifes‐
tations over a period of up to 15 days once the offending agent is withdrawn [223]. AGEP has
a favourable prognosis; the reported mortality rate is up to 5% and poor outcomes usually
result from secondary infection in the elderly or those patients with significant comorbidities
[227],[228].
6.4. Etiology
AGEP is caused by drugs in at least 90% of cases. According to the EuroSCAR study, the agents
conferring the highest risk are pristinamycin, aminopenicillins, hydroxychloroquine, antibac‐
terial sulphonamides, terbinafine and diltiazem [18]. The latent period is short (usually 1-5
days) with the EuroScar study demonstrating that it may vary for different drugs. For
antibiotics, including sulphonamides, the median latent period was 1 day, and for other drugs
it was 11 days [18].
Contact sensitivity has been implicated in a few case reports. Causative agents include
mercury[229], and bufexemac, a potent topical NSAID[230]. Neither of these agents was
implicated in the 97 cases of AGEP in the EuroScar. The role of infectious agents in AGEP has
been suggested in various case reports due to the absence of an inciting drug [231]. The
organisms include coxsackie B4 [232], cytomegalovirus [233], parvovirus B19 [234], Chlamydia
pneumoniae [235], and Escherichia coli [236]. No significant risk for infection was found in the
EuroScar study although the study was not designed to identify potential causative organisms.
Spider bites were suggested as a cause AGEP in a series of three cases from Israel, presumably
as a result of the venom’s ability to induce IL-8 and GM-CSF [237]. Finally, as illustrated in
two recent cases, AGEP may develop without preceding medication or disease [238].
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 (a) 
(b) 
) 
(c) 
Figure 13. This patient with AGEP had an onset of erythema and edema of the face (A), erythema of the trunk (B)
with a predilection for intertriginous areas (C).
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6.5. Pathogenesis
The pathogenesis of AGEP has been elucidated by patch [239],[240] and in vitro tests [241]-
[243] and initially involves activation, expansion and subsequent migration of drug-specific
CD4 and CD8 cells to the skin. The initial influx of CD8 cytotoxic T cells results in apoptosis
of keratinocytes and the formation of subcorneal vesicles. The infiltrating CD4 cells release
CXCL-8, which results in recruitment of neutrophils, and granulocyte macrophage-colony
stimulating factor (GM-CSF), which prevents apoptosis of neutrophils. This results in the
conversion of vesicles into pustules. CD4 cells also release IFN-γ, which stimulates keratino‐
cytes to secrete CXCL-8, as well as RANTES and IL-5, which contributes to the eosinophilia
observed in some patients [244]. Resident Langerhans’ cells may present drug antigens to CD4
cells and keratinocytes may act as antigen presenting cells to CD8 cells thereby augmenting
the neutrophil-mediated inflammatory response. Genetic susceptibility to AGEP has not been
robustly examined and therefore remains largely unknown.
6.6. Diagnostic tests
A pustular smear should be performed to exclude an infectious aetiology. A full blood count
will reveal a neutrophilia. A skin biopsy may show (spongiform or non-spongiform) subcor‐
neal and/or intradermal pustules, edema of the papillary dermis, perivascular infiltrates with
neutrophils and exocytosis of some eosinophils and focal necrotic keratinocytes (Fig. 15). The
typical changes of psoriasis such as acanthosis and papillomatosis are usually absent. Patch
testing may be useful in confirming the association between AGEP and the culprit drugs. In a
Figure 14. The lesions of AGEP occur rapidly and are characterized by dozens of small (< 5 mm) non-follicular sterile
pustules.
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controlled study, patch tests were positive in half of the 14 cases of AGEP [96]. Readings should
not be restricted to 24 and 48 hours after the application of the drug but should also be
determined at 96 and 120 hours to maximise sensitivity. Pustule formation is often observed
in positive patch tests in cases of AGEP. The test can be conducted one month after resolution
of the disease. The risk of AGEP with patch testing is considered to be low but not negligible
[245]. A small number of studies have supported a role for LTT [246], IFN-γ release [247],
lymphokine macrophage migration inhibition factor release assays [241] but these in vitro tests
are not widely available and its value remains to be determined in large cohorts.
Figure 15. A moderate power view of a skin biopsy from a patient with AGEP shows spongiform subcorneal pustules,
edema of the papillary dermis and perivascular infiltrates with neutrophils and exocytosis of some eosinophils.
Morphology
Pustules
Typical +2
Compatible with disease +1
Insufficient 0
Erythema
Typical +2
Compatible with disease +1
Insufficient 0
Distribution
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Morphology
Pustules
Typical +2
Compatible with disease +1
Insufficient 0
Post pustular desquamation
Yes +1
No 0
Course
Mucous membrane involvement
Yes -2
No 0
Acute onset
Yes 0
No -2
Resolution
Yes 0
No -4
Fever ≥ 38°C
Yes +1
No 0
Polymorphonuclear cells ≥ 7/μl
Yes +1
No 0
Histology
Other disease -10
Not representative 0
Exocytosis of polymorphonuclear cells +1
Subcorneal and/or intraepidermal non-spongiform pustules or
NOS pustules with papillary edema or subcorneal and/or
intraepidermal spongiform pustulea or NOS pustules without
papillary edema
+2
Spongiform subcorneal and/or intraepidermal pustules with
papillary edema
+3
NOS, not otherwise specified.
Score ≤ 0; excluded, 1-4: possible, 5-7: probable, 8-12: definite
Table 6. Diagnostic score for validation of AGEP
Severe Cutaneous Adverse Reactions
http://dx.doi.org/10.5772/54820
83
6.7. Differential diagnosis
AGEP, which is characterized by non-follicular pustules can be readily distinguished from
diseases with follicular pustulosis such as bacterial folliculitis, furunculosis, acneiform
eruptions, pustular contact dermatitis, dermatophyte infection, viral exanthema with primary
vesiculation and secondary postulation, impetigo, Sweet syndrome and SSSS. Other diseases
are not as easily differentiated from AGEP. Generalized pustular psoriasis (Zumbusch
psoriasis) is characterized by pustules that slowly develop on areas of psoriasis accompanied
by the histological changes of psoriasis on skin biopsy. There is also usually a family history
of psoriasis. Sneddon-Wilkinson disease (subcorneal pustulosis) and subcorneal IgA derma‐
tosis are characterized by the subacute development of larger pustules than those that erupt
in AGEP and maybe associated with hyopyon formation.
A diagnostic score was devised to validate the diagnosis of AGEP based on the morphology,
course of disease, and histology and assist in the differentiation from similar diseases [223].
6.8. Treatment
As AGEP is a self-limiting disease with a favourable prognosis. Cessation of the causative agent
and supportive treatment is usually all that his required. In the pustular phase, supportive
measures consist of moist dressings with drying and disinfecting solutions to avoid superin‐
fection. In the postpustular desquamation phase, emollients are used to optimise preservation
of skin barrier function. In a study of nine cases from Israel, all of who made a full recovery,
seven received supportive care alone and the other two received corticosteroids [248]. It
remains to be established whether oral or parenteral corticosteroids hasten the resolution of
disease. A brief course of systemic corticosteroids may be considered in patients with severe
and widespread inflammation of the skin.
7. Conclusion
SCARs such as SJS/TEN, DIHS/DRESS, and AGEP are idiosyncratic and specific types of
reactions that have distinct clinical, laboratory and histological features. The definition of
DIHS/DRESS has not been universally adopted and will need to be clarified once the role of
herpetic viruses and characteristic histological features are known. The early identification of
these reactions and the subsequent prompt withdrawal of therapy and the implementation of
supportive and adjunctive therapies are crucial in minimising morbidity and rates of mortality.
Multicentre randomized studies are required to adopt the most suitable therapies for these
potentially life-threatening conditions. The emergence in the understanding of HLA suscept‐
ibility genes will enable patients to be screened for the risk of developing a SCAR and will
hopefully be more widely performed once cost effective and rapid methods of detection are
widely available to the prescribing doctor.
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